混合PET/MRI在主要癌症中的应用:范围综述
该范围综述系统检索了PubMed/MEDLINE、Embase和Cochrane Library,纳入2012-2018年发表的116项评估PET/MRI在脑外癌症诊断性能的研究。数据提示18F-FDG PET/MRI在鼻咽癌分期和高风险乳腺癌肝转移检测中优于PET/CT,68Ga-PSMA-11 PET/MRI对前列腺癌局部复发检测优于PET/CT,但结论基于小样本数据。
要点
- FDG PET/MRI在鼻咽癌分期和高风险乳腺癌肝转移检测中优于PET/CT。
- 68Ga-PSMA-11 PET/MRI对前列腺癌局部复发检测优于PET/CT。
- FDG PET/MRI在头颈癌和乳腺癌肺转移检测中劣于PET/CT。
核心结论
- 有证据支持FDG PET/MRI用于鼻咽癌分期和高风险乳腺癌分期。
- 初步数据提示PET/MRI在前列腺癌局部复发、宫颈癌局部肿瘤侵犯和结直肠癌肝转移检测中具有优势。
- 上述结论基于小样本数据,需进一步研究验证。
研究设计与样本
- 范围综述,系统检索PubMed/MEDLINE、Embase和Cochrane Library。
- 共识别3138篇出版物,纳入2012-2018年发表的116项研究。
- 纳入研究按主要癌症类型分组:头颈癌13项、乳腺癌9项、前列腺癌21项、妇科肿瘤14项、胃肠道癌13项、其他各类癌症46项。
主要发现
- 比较PET/MRI与PET/CT用于分期/再分期的研究数据提示,18F-FDG PET/MRI在鼻咽癌肿瘤范围及咽后淋巴结转移检测中优于PET/CT。
- FDG PET/MRI在高风险乳腺癌肝转移及可能的骨髓转移检测中优于PET/CT。
- FDG PET/MRI在头颈癌和乳腺癌肺转移检测中趋于劣于PET/CT。
- 68Ga-PSMA-11 PET/MRI在前列腺癌局部复发检测中优于PET/CT。
- FDG PET/MRI在宫颈癌局部肿瘤侵犯检测中优于FDG PET/CT,在结直肠癌肝转移检测中准确率更高。
临床怎么用
- 可考虑将FDG PET/MRI用于鼻咽癌分期和高风险乳腺癌分期。
- 前列腺癌局部复发检测可考虑68Ga-PSMA-11 PET/MRI。
- 宫颈癌局部侵犯和结直肠癌肝转移检测可考虑FDG PET/MRI。
- 头颈癌和乳腺癌肺转移检测时需注意FDG PET/MRI可能劣于PET/CT。
局限性
- 范围综述方法学识别出大量记录,但不足5%适合纳入。
- 仅有限研究允许得出PET/MRI与PET/CT在肿瘤学中优劣的结论。
- 结论基于小样本数据集,需进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: PET/MRI was introduced for clinical use in 2011 and is now an established modality for the imaging of brain and certain pelvic cancers, whereas clinical use for the imaging of other forms of cancer is not yet widespread. We therefore systematically investigated what has been published on the use of PET/MRI compared to PET/CT in the imaging of cancers outside the brain, focusing on clinical areas of application related to diagnosis, staging and restaging. METHODS: A systematic search of PubMed/MEDLINE, Embase and the Cochrane Library was performed. Studies evaluating the diagnostic performance of simultaneous PET/MRI in cancer patients were chosen. RESULTS: A total of 3,138 publications were identified and 116 published during the period 2012-2018 were included and were grouped according to the major cancer forms: 13 head and neck (HNC), 9 breast (BC), 21 prostate (PC), 14 gynaecological, 13 gastrointestinal (GIC), and 46 various cancers. Data from studies comparing PET/MRI and PET/CT for staging/restaging suggested the superiority of 18F-FDG PET/MRI for the detection of tumour extension and retropharyngeal lymph node metastases in nasopharyngeal cancer, and for the detection of liver metastases and possibly bone marrow metastases in high-risk BC. FDG PET/MRI tended to be inferior for the detection of lung metastases in HNC and BC. 68Ga-PSMA-11 PET/MRI was superior to PET/CT for the detection of local PC recurrence. FDG PET/MRI was superior to FDG PET/CT for the detection of local tumour invasion in cervical cancer and had higher accuracy for the detection of liver metastases in colorectal cancer. CONCLUSION: The scoping review methodology resulted in the identification of a huge number of records, of which less than 5% were suitable for inclusion and only a limited number allowed conclusions on the advantages/disadvantages of PET/MRI compared to PET/CT in the oncological setting. There was evidence to support the use of FDG PET/MRI in staging of nasopharyngeal cancer and high-risk BC. Preliminary data indicate the superiority of PET/MRI for the detection of local recurrence in PC, local tumour invasion in cervical cancer, and liver metastases in colorectal cancer. These conclusions are based on small datasets and need to be further explored.
引用
- Morsing A, Hildebrandt MG, Vilstrup MH, et al. Hybrid PET/MRI in major cancers: a scoping review. Eur J Nucl Med Mol Imaging. 2019. PMID: 31267161. doi:10.1007/s00259-019-04402-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。